Abbott said he had received approval from the United States. The Food and Drug Administration (FDA) will launch the Liberta RC DBS system, the world's most minor deep brain stimulation (DBS) device with remote sensing capabilities to treat people with movement disorders.
In addition, the Liberta RC DBS system has the lowest costs of any FDA-cleared DBS system, meaning most people only need ten injections per year. Person to physician communication is essential to effective care, especially for patients with chronic conditions such as Parkinson's disease and tremors that can be treated with brain stimulation therapy. The Liberta RC DBS system allows people to communicate with their doctors, make accurate appointments, provide services and receive the latest treatment options whenever needed without ever setting foot in a doctor's office or practice.
Abbott developed the NeuroSphere Virtual Clinic based on research showing that the average Abbott DBS user in the United States has to travel more than 150 miles to see a movement specialist."When patients choose reversible DBS systems, they do so because of the small size of the device, but the effect of the loading frequency on the presence of patience," said Dr. Paul Larson, professor of neurosurgery at the University of Arizona. The Liberta RC system DBS excels in both areas as a compact, portable device with the lowest cost requirements of any FDA-approved DBS system. This achievement and the introduction of remote programming capabilities represent a significant patient advance.
, CDSCO.jpg)
.jpg)